Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis

N. Çakici, N. J. M. van Beveren, G. Judge-Hundal and 2 more

Psychological Medicine · 2019 · Meta-analysis

doi:10.1017/s0033291719001995

Abstract

Background. Accumulating evidence shows that a propensity towards a pro-inflammatory status in the brain plays an important role in schizophrenia. Anti-inflammatory drugs might compensate this propensity. This study provides an update regarding the efficacy of agents with some anti-inflammatory actions for schizophrenia symptoms tested in randomized controlled trials (RCTs).

Methods. PubMed, Embase, the National Institutes of Health website (http://www.clinicaltrials.gov), and the Cochrane Database of Systematic Reviews were systematically searched for RCTs that investigated clinical outcomes.

Results. Our search yielded 56 studies that provided information on the efficacy of the following components on symptom severity: aspirin, bexarotene, celecoxib, davunetide, dextromethorphan, estrogens, fatty acids, melatonin, minocycline, N-acetylcysteine (NAC), pioglitazone, piracetam, pregnenolone, statins, varenicline, and withania somnifera extract. The results of aspirin [mean weighted effect size (ES): 0.30; n = 270; 95% CI (CI) 0.06–0.54], estrogens (ES: 0.78; n = 723; CI 0.36–1.19), minocycline (ES: 0.40; n = 946; CI 0.11–0.68), and NAC (ES: 1.00; n = 442; CI 0.60–1.41) were significant in meta-analysis of at least two studies. Subgroup analysis yielded larger positive effects for first-episode psychosis (FEP) or early-phase schizophrenia studies. Bexarotene, celecoxib, davunetide, dextromethorphan, fatty acids, pregnenolone, statins, and varenicline showed no significant effect.

Conclusions. Some, but not all agents with anti-inflammatory properties showed efficacy. Effective agents were aspirin, estrogens, minocycline, and NAC. We observed greater beneficial results on symptom severity in FEP or early-phase schizophrenia.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The pathophysiology of schizophrenia is still not completely understood, but there is accumulating evidence that dysregulations in components of the immune system are fundamentally linked to the disease. While genetic associations show that people with schizophrenia on average have an immune system subtly more prone to activation, as expressed e.g. in major histocompatibility complex molecules (Debnath et al.,; Mokhtari and Lachman, ), its enhancers (Takao et al., ), and complement factor 4 (Sekar et al., ), environmental circumstances that naturally activate the immune system such as prenatal infection, trauma, and stress, may put components of the immune system (i.e. microglia) in an altered state of activity (Brown and Derkits,; Fineberg and Ellman, ). Under such circumstances, microglia and other glia may reduce their neurotrophic function and produce less growth factors such as brain-derived neurotrophic factor (BDNF), leading to decreased proliferation of neurons, resulting in reduced connectivity and, finally, brain tissue degradation. In addition, pruning may be increased by opsonization of synaptic buds with activated complement (Nimgaonkar et al.,; Presumey et al., ). Glutamatergic and dopaminergic neurotransmissions are particularly vulnerable for an increased activation of microglia, which can induce or exacerbate positive, negative, and cognitive symptoms of schizophrenia (Muller and Schwarz,; Muller and Dursun, ).

Over the years, many studies have presented evidence to support this theory. A schizophrenia genome-wide association study found associations between schizophrenia and certain genes that are involved in immune processes (Schizophrenia Working Group of the Psychiatric Genomics, ). Peripheral blood markers, such as BDNF, interleukin (IL)-10, and C-reactive protein (CRP), are associated with cognitive decline in schizophrenia (Liu et al.,; Man et al.,; Misiak et al., ). Interestingly, a recent study identified macrophages on the brain side of the endothelial wall in a subgroup of patients with schizophrenia but not in controls, demonstrating an influx of peripheral immune cells (Cai et al., ).

The immune hypothesis readily suggests a possible treatment for those patients with schizophrenia in which the underlying pathophysiology is related to a subtle increase in the activation of microglia. Many medications can decrease the production of pro-inflammatory factors; however, it is not certain whether these agents can induce microglia, astrocytes, and other cells to resume their normal neurotrophic functions (Chew et al.,; Sommer et al., ). For one frequently used anti-inflammatory drug, minocycline, Sellgren et al. showed that this drug was indeed able to reduce microglia engulfment of complement opsonized synapses in a stem cell model derived from patients (Sellgren et al., ). This finding suggests that at least minocycline, but perhaps also other anti-inflammatory drugs, can correct one of the basic mechanisms underlying schizophrenia. Yet, components that work in vitro do not always work in vivo.

In a previous meta-analysis on augmentation with anti-inflammatory medications, we showed beneficial results of aspirin, estrogens, and N-acetylcysteine (NAC) on symptom improvement in patients with schizophrenia (Sommer et al., ), though based on very few studies. However, since the publication of our previous meta-analysis, a substantial number of additional studies have investigated the same and other agents with potential anti-inflammatory properties, which could reinstate the balance between synaptogenesis and pruning in schizophrenia and possibly improve symptoms. We have listed in Table 1 treatments with known anti-inflammatory actions, how well the blood-brain-barrier (BBB) can be crossed, and their actions in the brain. This summary is incomplete, as many nutritional and herbal components also possess anti-inflammatory aspects. Additionally, many psychotropic agents such as antipsychotics, selective serotonin reuptake inhibitors, lithium, and valproate acid also have some anti-inflammatory actions. As shown in Table 1, most anti-inflammatory components have many functions, and their anti-inflammatory actions are just one of them and often not the most important one. Some of these agents have been given to patients with schizophrenia in an attempt to normalize the brain's immune system and to eventually reduce symptoms. Here, we quantitatively summarize all available evidence of drugs with some anti-inflammatory aspects studied in patients with schizophrenia in a double-blind randomized design.

Literature search

The literature was systematically reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (Moher et al., ). Two independent investigators (N.Ç. and G.E.) systematically searched PubMed, Embase, the National Institutes of Health website (http://www.clinicaltrials.gov), and the Cochrane Database of Systematic Reviews from inception to 9 August 2018. No language or year restrictions were applied. The search strategy used for each database can be found in online Supplementary Material S1.

Inclusion criteria

Consensus on the studies included was reached on the basis of the following criteria: Randomized, double-blind, placebo-controlled trials regarding augmentation of antipsychotic medication with anti-inflammatory agents.Patients included had a diagnosis of a schizophrenia spectrum disorder (schizophrenia, schizophreniform disorder, or schizoaffective disorder) according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III, DSM-III-R, DSM-IV, and DSM-IV-TR or International Classification of Diseases, 9th or 10th revision). Schizotypal and schizoid personality disorder were not included.Studies reported information to calculate common effect size (ES) statistics of change scores, i.e. means and standard deviations; exact p, t, or z values; or corresponding authors could supply these data upon request. Studies providing only post-treatment data were not included.We also included crossover studies to obtain as much information as possible. We excluded antipsychotic, antidepressant, and mood-stabilizing agents because their well-known efficacy on symptom severity would confound the results. Studies that were only published as abstracts were included after contacting the authors for more detailed information. If multiple publications from the same cohort were available, we extracted data from the largest or most recent data set.

Randomized, double-blind, placebo-controlled trials regarding augmentation of antipsychotic medication with anti-inflammatory agents.

Patients included had a diagnosis of a schizophrenia spectrum disorder (schizophrenia, schizophreniform disorder, or schizoaffective disorder) according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III, DSM-III-R, DSM-IV, and DSM-IV-TR or International Classification of Diseases, 9th or 10th revision). Schizotypal and schizoid personality disorder were not included.

Studies reported information to calculate common effect size (ES) statistics of change scores, i.e. means and standard deviations; exact p, t, or z values; or corresponding authors could supply these data upon request. Studies providing only post-treatment data were not included.

Outcome measures

The primary outcome measure was the mean change in total score on the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS). We also investigated effects on PANSS positive, PANSS negative, and cognitive test batteries. Data of the last observation carried forward analysis were used when provided. If only data of completer analyses were given, these data were used instead. The quality of the studies was assessed using the Cochrane risk of bias tool for randomized trials (Higgins et al., ). Two reviewers (N.Ç. and G.E.) independently extracted data from the papers. Disagreements were resolved by discussion or by a third reviewer (I.E.S.).

Statistical analyses

We calculated standardized differences from the mean differences (placebo v. augmentation) of the change score (end of treatment minus baseline) means and standard deviations (Rosenthal, ). When only exact F or p values for the main effects of the treatment group were presented, these data were used. We calculated standardized mean differences, represented as Hedges' g (Shaddish and Haddock, ), using a random-effects model. Inconsistency across studies was assessed with the I2 statistic (Higgins et al., ), with values ⩾50% indicating high heterogeneity, and values between 30% and 50% indicating moderate heterogeneity. Potential publication bias was assessed using the Egger test of the intercept if 10 or more studies were analysed for the same anti-inflammatory therapy and represented diagrammatically with funnel plots (Egger et al., ), as recommended by the Cochrane Collaboration (online Supplementary Figs S1–S3) (Higgins and Green, ). Subgroup analyses were performed to investigate the effects of anti-inflammatory medication in distinct patient groups, including first-episode psychosis (FEP), early-phase schizophrenia (duration of illness ⩽ 5 years) and chronic schizophrenia (duration of illness > 5 years). Meta-regression of categorical moderators was performed if at least four studies were available. In turn, meta-regression of continuous moderators was performed if at least six studies were available (Fu et al., ). Following this rule, we assessed the effects of the following moderators: study quality, illness duration, treatment duration, treatment dose, and baseline severity score (as measured with the PANSS total). Results of meta-analysis and meta-regression with a p value < 0.05 were considered significant. Results of multiple testing, using the Bonferroni correction (Haynes, ), are presented in addition to uncorrected findings for interpretation of the reader. All analyses were performed using Comprehensive Meta-Analysis version 2.0.

Results

A total of 56 studies were retrieved by our search that fulfilled all inclusion criteria (Fig. 1). These studies provided information on the efficacy of the following agents on the improvement of symptom severity in patients with schizophrenia: aspirin, bexarotene, celecoxib, davunetide, dextromethorphan, estrogens, fatty acids including eicosapentaenoic acids (EPA) and docosahexaenoic acids (DHA), melatonin, minocycline, NAC, pioglitazone, piracetam, pregnenolone, statins, varenicline, and withania somnifera extract (WSE). Figure 2 shows the effect sizes of the effects of anti-inflammatory medication on symptom severity. Effect size estimates for individual studies are provided in online Supplementary Figs S4–S19.

Additional study characteristics such as treatment duration and treatment dose are provided in online Supplementary Table S1. A detailed description of the effects of anti-inflammatory agents on positive and negative symptoms can be found in online Supplementary Material S2 and online Supplementary Figs S20–S46. Quality of the studies varied from fair to good quality (online Supplementary Table S2).

Aspirin

Aspirin is an NSAID that modifies cyclooxygenase-2 (COX-2) activity and irreversibly inhibits cyclooxygenase-1 (COX-1), thereby suppressing the production of prostaglandins and thromboxanes, which are involved in the inflammatory process (Roth and Majerus,; Vane et al., ). Aspirin also reduces hypothalamic-pituitary-adrenal axis response (Nye et al., ). The BBB is not readily crossed by aspirin, and aspirin levels in the central nervous system are lower than in peripheral blood (Vasovic et al., ). Two studies provided 1000 mg aspirin daily to schizophrenia patients in addition to their regular treatment for 3 (Laan et al., ) or 4 months (Weiser et al., ). A significant positive influence on total symptom severity was observed [mean weighted effect size (ES): 0.30; 95% confidence interval (CI) 0.06–0.54; p = 0.014; heterogeneity (I2) = 0%].

Bexarotene

Bexarotene is an antitumor agent that acts via the nuclear retinoid X receptor (RXR) (Lerner et al., ). Activation of RXR has the potential to increase apolipoprotein E, which inhibits the complement pathway (Tousi,; Yin et al., ). Bexarotene can easily cross the BBB (Tousi, ). One study investigated the effects of bexarotene 75 mg/day for 6 weeks on symptom severity in schizophrenia patients. However, bexarotene did not significantly improve symptom severity (ES: 0.37; CI −0.05 to 0.78; I2 = 0%).

Celecoxib

Celecoxib is also an NSAID and has analgesic and inflammatory actions as well. Celecoxib reduces pain and inflammation by blocking COX-2-mediated vascular permeability, thereby reducing extravasation of pro-inflammatory cells, proteins, and enzymes, which enhance the local inflammatory response and lead to edema (Simon, ). Celecoxib is a small molecule that can easily cross the BBB (Davies et al., ). In all five included studies, a dose of 400 mg was provided to schizophrenia patients, and duration of treatment varied from 5 to 11 weeks (Muller et al.,,; Rappard and Muller,; Rapaport et al.,; Akhondzadeh et al., ). We observed heterogeneous results, ranging from strong positive to strong negative effects of celecoxib as augmentation therapy. The effects of celecoxib on the symptom severity was not significant (ES: 0.15; CI −0.67 to 0.96), and heterogeneity was high (I2 = 93%).

Davunetide

Davunetide is the smallest active element from the activity-dependent neuroprotective protein, which can readily enter the BBB from the blood (Quintana et al., ). Davunetide can downregulate key inflammatory cytokines (Quintana et al., ). We included one study that provided davunetide (5 or 30 mg daily) as augmentation therapy to patients with chronic schizophrenia for 3 months (Javitt et al., ). Neither dose improved symptom severity (ES: −0.24; CI −0.65 to 0.19; I2 = 0%).

Dextromethorphan

Dextromethorphan, an antitussive drug, has neuroprotective and anti-inflammatory effects by inhibiting overactivation of microglia (Zhang et al., ). One study provided 60 mg dextromethorphan daily in addition to standard treatment to patients with schizophrenia for 11 weeks (Lee et al., ). Dextromethorphan did not improve symptom severity (ES: 0.11; CI −0.29 to 0.52; I2 = 0%).

EPA and DHA fatty acids

Fatty acids, especially EPA and DHA fatty acids, have several mild anti-inflammatory effects, such as decreasing levels of serum IL-1β, tumor necrosis factor alpha (TNF-α) and interferon-γ levels, and neuroprotective effects (Solfrizzi et al.,; Calder, ). Fatty acids also enhance synaptic plasticity and membrane fluidity and affect dopaminergic, serotonergic, and glutamatergic neurotransmission (Glantz and Lewis,; Calder, ). Eleven studies were included, of which seven studies added EPA, one study added DHA, and four studies added omega-3 fatty acids (i.e. combination of EPA and DHA) to antipsychotic treatment for patients with schizophrenia (Fenton et al.,; Peet et al.,; Peet and Horrobin,; Emsley et al.,,,; Berger et al.,; Bentsen et al.,; Jamilian et al.,; Boskovic et al.,; Pawelczyk et al., ). Daily treatment doses of fatty acids varied (EPA 0.5 g to 4 g, DHA 2 g, omega-3 0.4 g to 2.2 g) as did treatment duration across the studies (8 weeks to 2 years). We observed a trend toward beneficial results for treatment with EPA and/or DHA fatty acids (ES: 0.19; CI −0.02 to 0.40; p = 0.075; I2 = 41%), without indication of publication bias (Egger test p = 0.45). One study reported a large negative ES of −0.64 and was regarded as an outlier in an additional analysis (Bentsen et al., ). Exclusion of this outlier yielded a mean weighted ES of 0.23, which was significant (CI 0.05–0.41; p = 0.012; I2 = 9%). Subgroup analysis showed a trend toward beneficial effects for FEP patients (ES: 0.31; CI −0.02 to 0.64; p = 0.064) (online Supplementary Table S3).

Estrogens

Estrogens, especially 17β-estradiol, have immunomodulatory effects by, e.g. regulating innate immune signalling pathways and modulating inflammatory elements such as cytokines (Medina-Estrada et al., ). Other properties of estrogens include reducing antioxidative stress, controlling energy balance and glucose homeostasis, and influencing dopaminergic neurotransmission (Liu et al., ). Eleven studies provided estrogen as augmentation therapy for patients with schizophrenia (Kulkarni et al.,,,,; Akhondzadeh et al.,; Louza et al.,; Ghafari et al.,; Kianimehr et al.,; Khodaie-Ardakani et al.,; Usall et al.,; Weiser et al., ). Nine studies included only females, and two studies included only males (Kianimehr et al.,; Khodaie-Ardakani et al., ). Four studies applied (ethinyl) estradiol (Kulkarni et al.,,,; Akhondzadeh et al., ), two studies applied conjugated estrogen (Louza et al.,; Ghafari et al., ), and five studies applied raloxifene, a selective estrogen receptor modulator (Kianimehr et al.,; Khodaie-Ardakani et al.,; Kulkarni et al.,; Usall et al.,; Weiser et al., ). Estrogen doses ranged from 0.05 mg per day (patch) to 2 mg per day (orally), and raloxifene doses varied from 60 mg to 120 mg per day (orally). One study reported a large ES of 3.7 and was regarded as an outlier (Ghafari et al., ). Exclusion of this outlier yielded a mean weighted ES of 0.57, which was significant (CI 0.25–0.90; p = 0.001; I2 = 74%). Indication of publication bias was found (Egger test p = 0.001). A significant ES was also found when we restricted analyses to female studies only (ES: 0.52; CI 0.18–0.87; p = 0.003; I2 = 72%).

Melatonin

Melatonin is a multifunctional hormone largely derived from the pineal gland at night under normal light and dark conditions. It is an antioxidant and also a widespread anti-inflammatory molecule, modulating both pro- and anti-inflammatory cytokines, which can easily pass the BBB (Favero et al., ). One study investigated the effects of adding 3 mg melatonin daily to regular antipsychotic treatment for patients with schizophrenia for 8 weeks (Modabbernia et al., ). Melatonin showed significant beneficial results on decreasing symptom severity in schizophrenia (ES: 2.82; CI 1.91–3.74; p < 0.001; I2 = 0%).

Minocycline

Minocycline is a broad-spectrum tetracycline antibiotic that has strong inhibitory effects on microglia cells and can easily cross the BBB (Watabe et al., ). Ten studies assessed the effect of minocycline augmentation therapy for schizophrenia patients (Levkovitz et al.,; Chaudhry et al.,; Ghanizadeh et al.,; Khodaie-Ardakani et al.,; Liu et al.,; Chaves et al.,; Kelly et al.,; Deakin et al.,; Zhang et al.,; Weiser et al., ). The daily treatments doses varied from 100 to 300 mg, and the duration of treatment was relatively long, ranging from 2 to 12 months. Minocycline treatment in addition to regular antipsychotic treatment showed significantly beneficial results on symptom severity (ES: 0.40; CI 0.11–0.68; p = 0.007; I2 = 77%), with an indication of publication bias (Egger test p < 0.001). One study reported a large negative ES of −0.24 (Deakin et al., ). Excluding this study from the analysis yielded a mean weighted ES of 0.47 (CI 0.18–0.76; p = 0.002; I2 = 72%). Subgroup analysis showed a trend toward positive effects for patients with early-phase schizophrenia (ES: 0.38; CI −0.02 to 0.78; p = 0.060) (online Supplementary Table S3).

N-acetylcysteine

NAC has evident anti-inflammatory properties and can modulate immune functions during the inflammatory response by inhibiting TNF-α, IL-1β, and IL-6 (Palacio et al., ). NAC can also easily pass the BBB (Farr et al., ). Five studies investigated the effects of NAC augmentation therapy on symptom severity of patients with schizophrenia (Berk et al.,; Farokhnia et al.,; Zhang et al.,; Breier et al.,; Sepehrmanesh et al., ). Only one of those studies restricted inclusion to FEP patients only (Zhang et al., ). Treatment doses varied from 600 mg to 3600 mg, and duration of treatment varied from 8 to 52 weeks. NAC as augmentation therapy had significant beneficial effects on decreasing symptom severity in patients with schizophrenia compared with controls (ES: 1.00; CI 0.60–1.41; p < 0.001; I2 = 75%). Subgroup analysis showed that augmentation therapy with NAC is beneficial in all illness stages, including FEP which yielded the largest ES (ES: 1.42; CI 1.02–1.81; p < 0.001), early-phase schizophrenia (ES: 0.98; CI 0.45–1.51; p < 0.001), and chronic schizophrenia (ES: 0.44; CI 0.11–0.77; p = 0.010) (online Supplementary Table S3).

Pioglitazone

Pioglitazone is an antidiabetic agent with antioxidant and anti-inflammatory actions (Iranpour et al., ), and it can cross the BBB (Grommes et al., ). One study provided 30 mg pioglitazone daily in addition to standard treatment for 8 weeks to patients with schizophrenia (Iranpour et al., ). Pioglitazone showed significant beneficial results on reducing symptom severity (ES: 0.79; CI 0.17–1.41; p = 0.012; I2 = 0%).

Piracetam

Piracetam is a nootropic analgesic agent and has anti-inflammatory effects. It can reduce TNF-α, IL-1β, and myeloperoxidase. There is some evidence that piracetam can cross the BBB (Brust, ). One study provided 3200 mg piracetam in addition to regular antipsychotic treatment for 8 weeks to schizophrenia patients (Noorbala et al., ). A significant positive influence on total symptom severity was observed (ES: 0.77; CI 0.05 to 1.50; p = 0.036; I2 = 0%).

Pregnenolone

Pregnenolone is a steroid hormone precursor that regulates neuron growth and cerebral BDNF levels (Naert et al.,; Murugan et al., ). Pregnenolone is also an anti-inflammatory molecule that can maintain immune homeostasis in various inflammatory conditions (Murugan et al., ). Pregnenolone can readily cross the BBB (Sripada et al., ). One study was included that added 50 mg pregnenolone to standard treatment for early-phase schizophrenia patients for 8 weeks (Ritsner et al., ). For this study, we observed no beneficial effects on the symptom severity (ES: 0.16; CI −0.34 to 0.67; I2 = 0%).

Statins

Statins are usually provided as primary or secondary prevention of cardiovascular diseases. Statins also have anti-inflammatory effects by reducing atherogenesis and, concomitantly, inflammation (Pearson et al., ). Statins can reduce levels of CRP and IL-6, and improve insulin resistance (Ridker et al.,; Guclu et al.,; Asanuma et al., ). The fat-soluble statins can easily cross the BBB (Sierra et al., ). Two studies provided statins in addition to regular antipsychotic treatment for patients with schizophrenia (Vincenzi et al.,; Tajik-Esmaeeli et al., ). Tajik-Esmaeeli et al. applied 40 mg simvastatin daily for 8 weeks and Vincenzi et al. applied 40 mg pravastatin for 12 weeks. However, beneficial effects on symptom severity were not observed (ES: 0.50; CI −0.25 to 1.25; I2 = 78%).

Varenicline

Varenicline is a high-affinity partial agonist at α7 nicotinic acetylcholine receptors (nAChRs) and is used to treat nicotine addiction. Varenicline can readily cross the BBB (Kurosawa et al., ). Activation of the vagus nerve reduces the production of pro-inflammatory cytokines from macrophages, such as TNF-α, in the spleen through a mechanism dependent on nAChRs (Rosas-Ballina and Tracey, ). It has been shown that varenicline administration reduces brain inflammation and promotes recovery of function following experimental stroke (Chen et al., ). Two studies provided varenicline in addition to antipsychotic treatment for patients with schizophrenia (Hong et al.,; Smith et al., ). Smith et al. applied 4 mg varenicline daily for 8 weeks and Hong et al. applied 1 mg varenicline for 8 weeks. No beneficial effects were observed on symptom severity (ES: 0.24; CI −0.13 to 0.61; I2 = 24%).

Withania somnifera extract

WSE, mostly used as a medicinal herb in Ayurvedic medicine, has anti-inflammatory actions (i.e. inhibition of NF-κβ inflammatory signalling pathways and COX-2) (Khan et al.,; Mulabagal et al., ). WSE consists of various phytochemicals, of which the effects of 1000 mg withaferin A on symptom severity was investigated in one study for 12 weeks (Chengappa et al., ). WSE with drug ligand withaferin A can readily cross the BBB (Kumar and Patnaik, ). A significant positive influence on total symptom severity was observed (ES: 0.81; CI 0.32–1.30; p = 0.001; I2 = 0%).

Effects of moderators

Meta-regression analysis showed that illness duration, treatment duration, treatment dose, and baseline severity were insignificant predictors of the ES estimates for the effects of augmentation with EPA and/or DHA fatty acids, estrogen and minocycline (online Supplementary Table S3). Study quality was not a significant moderator for the celecoxib, EPA and/or DHA fatty acids, estrogen, minocycline and NAC studies.

Cognition

Eighteen studies investigated the effects of anti-inflammatory agents on cognition (online Supplementary Table S4). Heterogeneity of the cognitive tests used across the studies was too great to make a quantitative review of these effects. Notwithstanding, it seemed that minocycline improved attention, executive functions and memory (Levkovitz et al.,; Liu et al., ), whereas davunetide (the 5 mg group) improved verbal learning and memory (Javitt et al., ). NAC (Sepehrmanesh et al., ) improved attention, memory, and executive functions. However, other studies did not observe any beneficial effects on cognition for minocycline (Chaudhry et al.,; Kelly et al.,; Deakin et al.,; Weiser et al., ) and NAC (Breier et al., ). For statins, only one study investigated the effects of pravastatin on cognition and did not observe any significant effects (Vincenzi et al., ). For varenicline, no cognitive improvement was observed by Smith et al.. For the anti-inflammatory components bexarotene, celecoxib, dextromethorphan, melatonin, pioglitazone, piracetam, pregnenolone, and WSE no data on cognitive effects were reported.

Discussion

In this meta-analysis, we quantitively reviewed the efficacy of various anti-inflammatory medications to reduce symptom severity in patients with schizophrenia. We could include data from 56 studies applying 16 different agents in addition to antipsychotic treatment. The results of aspirin, estrogens, minocycline, and NAC showed significantly better results than placebo in meta-analysis of at least two studies, while pioglitazone, piracetam, and WSE were significant in single studies. Bexarotene, celecoxib, davunetide, dextromethorphan, fatty acids, pregnenolone, statins, and varenicline showed no significant beneficial effects.

Effects on symptom severity of specific components

Aspirin was found to have beneficial effects on symptom severity in our current study. It is important to note that aspirin has broadly active substances, and it is unclear whether the beneficial effects of aspirin are solely due to its anti-inflammatory properties. Celecoxib, which is a more specific anti-inflammatory agent, showed no beneficial effects. Another meta-analysis found that celecoxib improved symptoms in FEP patients but not in chronic patients (Zheng et al., ).

Fatty acids as augmentation therapy for patients with schizophrenia showed borderline significant effects on decreasing symptom severity in the current study. However, the included studies showed great heterogeneity in the methods of treatment. Researchers investigated the addition of different fatty acids (i.e. EPA or DHA) or a combination of fatty acids (i.e. EPA and DHA combined). Furthermore, three research groups added antioxidants to the fatty acids treatment regime (Bentsen et al.,; Emsley et al.,; Boskovic et al., ). So, in fact, several different treatment conditions are investigated under the umbrella term ‘fatty acids augmentation’. We also point out that, considering fatty acids augmentation (without anti-oxidants), the results showed a negative association, but this result was greatly influenced by a substantial outlier. Excluding this outlier showed a positive significant association. Furthermore, we observed that FEP patients might benefit the most from treatment with fatty acids compared with patients with a longer illness duration.

In summary, based on the available data, a clear statement about the efficacy of fatty acids, either alone or in combination with anti-oxidants cannot be made yet. Possibly, fatty acids can be beneficial, but the field is still investigating what specific combination of fatty acids is efficacious, and whether or not antioxidants are beneficial. Further research is warranted before a clear recommendation can be made.

Estrogen augmentation therapy for schizophrenia patients showed beneficial effects for a relatively short duration of treatment (starting at 4 weeks). Estrogens act on different ways in the brain and may cause their beneficial effects by mechanisms that are not related to inflammation (e.g. by affecting angiotensin and neurotransmission) (O'Dell et al.,; Sanchez et al., ).

Minocycline has strong inhibitory effects on microglia cell activation and may, therefore, be expected to have potential as augmentation therapy for schizophrenia (Inta et al., ). Microglia activation plays an important role during brain development, but excessive microglia activation is also considered a hallmark of neuroinflammation (Inta et al., ). Complex variations were found in the complement component 4A (C4A) gene in schizophrenia patients. Human C4 protein is localized to neuronal synapses, axons, dendrites, and cell bodies. These results of high complement activity in the development of schizophrenia could explain the reduced numbers of synapses in the brains of patients with schizophrenia (Sekar et al., ).

In the current meta-analysis, we found a clear positive result on amelioration of symptom severity and especially in early-phase schizophrenia. However, it should be noted that a large negative study was part of our analysis which provided almost 22% of the total amount of patients (Deakin et al., ). Deakin and colleagues investigated first-episode patients with an illness duration shorter than 5 years. Minocycline seems to have great beneficial effects on improving negative symptoms in schizophrenia (online Supplementary Fig. S40). We noted that the study population studied by Deakin and colleagues had relatively low baseline levels of PANSS negative symptoms (±17) compared with other studies investigating early-phase schizophrenia patients (>22).

NAC has clear anti-inflammatory and immune-modulating actions. All five studies included in this meta-analysis showed beneficial effects on improving symptom severity. Only one study restricted inclusion to FEP patients and yielded the largest beneficial effects on symptom severity (Zhang et al., ).

Simvastatin showed beneficial effects on improvement of symptom severity (Tajik-Esmaeeli et al., ), while pravastatin showed no positive significant effects on symptom severity. The difference can be explained by the fact that simvastatin easily crosses the BBB, while pravastatin does not. We found no significant effects of statins on symptom severity when these two studies were combined. More studies are needed to assess the efficacy of statins, especially of fat-soluble statins on symptom severity in schizophrenia.

Effects on cognition

The variety in cognitive assessment tests across the 18 studies that investigated the effects of anti-inflammatory medication on cognition was large. We observed that minocycline, NAC, and davunetide could have some cognitive enhancing properties but future research is needed.

Side effects

Reconsidering the five agents that showed positive results in a meta-analysis of at least two studies, it is worthwhile to consider the side effects of these anti-inflammatory agents. Aspirin use increases the risk of gastrointestinal bleeding and should, therefore, be combined with gastric protection. This serious side effect does not happen infrequently and, therefore, should be considered and monitored. On the other hand, aspirin also possesses cardioprotective properties, which can be beneficial in schizophrenia patients with metabolic syndrome.

Estrogens are not safe for a longer treatment duration than 1–2 months unless combined with progesterone. Estrogens such as raloxifene are sometimes accompanied by hot flashes and gastrointestinal problems. There are potential risks for the occurrence of thromboembolic events and fatal stroke in women with or at increased risk for cardiovascular disease. Therefore, the clinical risk for thromboembolic events should be evaluated and monitored during treatment (Barrett-Connor et al.,; Adomaityte et al., ).

Fatty acids are usually well tolerated. There are some reported side effects during administration such as gastrointestinal effects (e.g. constipation or diarrhea) and infection (e.g. upper respiratory infection). The omega-3 fatty acid and anti-oxidant combination might be beneficial (Bentsen et al.,; Bentsen and Landro, ).

NAC is a well-tolerated drug that can also be administered during pregnancy. NAC has other beneficial effects in schizophrenia, such as attenuating addiction (Gipson, ) and given that it is a free radical scavenger (Markoutsa and Xu, ). The NAC-varenicline combination may be beneficial in schizophrenia (Koola, ).

Minocycline is a tetracyclic antibiotic that can be given to a diverse group of patients with schizophrenia. In the included studies, no serious adverse events were observed in the treatment groups.

Limitations

An important limitation is that many anti-inflammatory augmentation treatment strategies have not been sufficiently investigated. Components with strong anti-inflammatory potency, such as glucocorticosteroids, have not been applied yet to patients with schizophrenia. Also, for most anti-inflammatory medications a limited number of studies was available. Most studies did not stratify schizophrenia patients in subgroups of illness duration. Furthermore, there was an insufficient description of signs of inflammation before the start of anti-inflammatory therapy. For designing future research it would be interesting to investigate whether signs of (low-grade) inflammation before the start of the trials would influence the outcome and degree of inflammation. There is increasing evidence from the biomarker research field that cytokine alterations are already present from disease-onset (Schwarz et al.,; Upthegrove et al.,; van Beveren et al., ). It would be interesting for further trials to stratify patients according to the presence of immune alterations and to investigate which inflammatory subtypes would benefit the most from anti-inflammatory therapy. This opens up the way for personalized medicine based on inflammatory markers.

Conclusion

The anti-inflammatory medications aspirin, estrogens, minocycline, and NAC improved symptom severity in patients with schizophrenia. We observed greater beneficial results in early-psychosis studies. Evidence for cognitive improvement is scarce. Taken together, there is evidence for the efficacy of some anti-inflammatory agents on symptom severity in schizophrenia which could confirm the immune hypothesis in schizophrenia, but further studies are still needed.

References 146

  1. 1.

    Adomaityte J, Farooq M and Qayyum R (2008 ) Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thrombosis and Haemostasis 99, 338–342.

    Not in our library

  2. 2.

    Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, Raisi F and Kamalipour A (2003 ) Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27, 1007–1012.

    Not in our library10.1016/s0278-5846(03)00161-1

  3. 3.

    Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH and Behnam B (2007 ) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90, 179–185.

    Not in our library10.1016/j.schres.2006.11.016

  4. 4.

    Aletaha D and Smolen JS (2018 ) Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA 320, 1360–1372.

    Not in our library10.1001/jama.2018.13103

  5. 5.

    Asanuma Y, Oeser A, Stanley E, Bailey DG, Shintani A and Stein CM (2008 ) Effects of C-reactive protein and homocysteine on cytokine production: modulation by pravastatin. Archives of Drug Information 1, 14–22.

    Not in our library10.1111/j.1753-5174.2007.00003.x

  6. 6.

    Azizian H, Khaksari M, Asadikaram G, Sepehri G and Najafipour H (2018 ). Therapeutic effects of tamoxifen on metabolic parameters and cytokines modulation in rat model of postmenopausal diabetic cardiovascular dysfunction: Role of classic estrogen receptors. International Immunopharmacology 65, 190–198.

    Not in our library10.1016/j.intimp.2018.10.009

  7. 7.

    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA and Wenger NK (2006 ) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New England Journal of Medicine 355, 125–137.

    Not in our library10.1056/nejmoa062462

  8. 8.

    Benros ME, Mortensen PB and Eaton WW (2012 ) Autoimmune diseases and infections as risk factors for schizophrenia. Annals of the New York Academy of Sciences 1262, 56–66.

    Not in our library10.1111/j.1749-6632.2012.06638.x

  9. 9.

    Bentsen H and Landro NI (2018 ) Neurocognitive effects of an omega-3 fatty acid and vitamins E + C in schizophrenia: a randomised controlled trial. Prostaglandins, Leukotrienes, and Essential Fatty Acids 136, 57–66.

    Not in our library10.1016/j.plefa.2017.10.002

  10. 10.

    Bentsen H, Osnes K, Refsum H, Solberg DK and Bohmer T (2013 ) A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Translational Psychiatry 3, e335.

    Not in our library10.1038/tp.2013.110

  11. 11.

    Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W and McGorry PD (2007 ) Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry 68, 1867–1875.

    Not in our library10.4088/jcp.v68n1206

  12. 12.

    Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ and Bush AI (2008 ) N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 64, 361–368.

    Not in our library10.1016/j.biopsych.2008.03.004

  13. 13.

    Boskovic M, Vovk T, Koprivsek J, Plesnicar BK and Grabnar I (2016 ) Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol. Nutritional Neuroscience 19, 156–161.

    Not in our library10.1179/1476830514y.0000000139

  14. 14.

    Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y and Francis MM (2018 ) Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophrenia Research 199, 395–402.

    Not in our library10.1016/j.schres.2018.03.012

  15. 15.

    Brown AS and Derkits EJ (2010 ) Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. American Journal of Psychiatry 167, 261–280.

    Not in our library10.1176/appi.ajp.2009.09030361

  16. 16.

    Brust P (1989 ) Reversal of scopolamine-induced alterations of choline transport across the blood-brain barrier by the nootropics piracetam and pramiracetam. Arzneimittel-Forschung 39, 1220–1222.

    Not in our library

  17. 17.
    Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation · 2018
    No notice
  18. 18.

    Calder PC (2012 ) Mechanisms of action of (n-3) fatty acids. Journal of Nutrition 142, 592s–599s.

    Not in our library10.3945/jn.111.155259

  19. 19.

    Chan ES and Cronstein BN (2010 ). Methotrexate--how does it really work? Nature Reviews: Rheumatology 6, 175–178.

    Not in our library10.1038/nrrheum.2010.5

  20. 20.

    Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G and Deakin B (2012 ) Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. Journal of Psychopharmacology 26, 1185–1193.

    Not in our library10.1177/0269881112444941

  21. 21.

    Chaves C, Marque CR, Maia-de-Oliveira JP, Wichert-Ana L, Ferrari TB, Santos AC, Araujo D, Machado-de-Sousa JP, Bressan RA, Elkis H, Crippa JA, Guimaraes FS, Zuardi AW, Baker GB, Dursun SM and Hallak JE (2015 ) Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophrenia Research 161, 439–445.

    Not in our library10.1016/j.schres.2014.11.031

  22. 22.

    Chen S, Bennet L and McGregor AL (2017 ) Delayed varenicline administration reduces inflammation and improves forelimb use following experimental stroke. Journal of Stroke and Cerebrovascular Diseases 26, 2778–2787.

    Not in our library10.1016/j.jstrokecerebrovasdis.2017.06.051

  23. 23.

    Chengappa KNR, Brar JS, Gannon JM and Schlicht PJ (2018 ) Adjunctive use of a standardized extract of Withania somnifera (Ashwagandha) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 79, 1.

    Not in our library10.4088/jcp.17m11826

  24. 24.

    Chew LJ, Fusar-Poli P and Schmitz T (2013 ) Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Developmental Neuroscience 35, 102–129.

    Not in our library10.1159/000346157

  25. 25.

    Davies NM, McLachlan AJ, Day RO and Williams KM (2000 ) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clinical Pharmacokinetics 38, 225–242.

    Not in our library10.2165/00003088-200038030-00003

  26. 26.
    The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial · 2018
    No notice
  27. 27.

    Debnath M, Cannon DM and Venkatasubramanian G (2013 ) Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry 42, 49–62.

    Not in our library10.1016/j.pnpbp.2012.07.009

  28. 28.

    Dodd S, Maes M, Anderson G, Dean OM, Moylan S and Berk M (2013 ) Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 42, 135–145.

    Not in our library10.1016/j.pnpbp.2012.11.007

  29. 29.

    Egger M, Davey Smith G, Schneider M and Minder C (1997 ) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629–634.

    Not in our library10.1136/bmj.315.7109.629

  30. 30.

    Emsley R, Myburgh C, Oosthuizen P and van Rensburg SJ (2002 ) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry 159, 1596–1598.

    Not in our library10.1176/appi.ajp.159.9.1596

  31. 31.

    Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, van Rensburg SJ, Maritz JS and Murck H (2006 ) The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophrenia Research 84, 112–120.

    Not in our library10.1016/j.schres.2006.03.023

  32. 32.

    Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, van Rensburg SJ and Harvey BH (2014 ) A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia Research 158, 230–235.

    Not in our library10.1016/j.schres.2014.06.004

  33. 33.

    Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O and Akhondzadeh S (2013 ) N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double- blind, placebo-controlled study. Clinical Neuropharmacology 36, 185–192.

    Not in our library10.1097/wnf.0000000000000001

  34. 34.

    Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA and Morley JE (2003 ) The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Journal of Neurochemistry 84, 1173–1183.

    Not in our library10.1046/j.1471-4159.2003.01580.x

  35. 35.
    Melatonin as an Anti-Inflammatory Agent Modulating Inflammasome Activation · 2017
    No notice
  36. 36.

    Fenton WS, Dickerson F, Boronow J, Hibbeln JR and Knable M (2001 ) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. American Journal of Psychiatry 158, 2071–2074.

    Not in our library10.1176/appi.ajp.158.12.2071

  37. 37.

    Ferreira AP, Pasin JS, Saraiva AL, Ratzlaff V, Rossato MF, Andrighetto R, Rubin MA, Ferreira J and Mello CF (2012 ) N-acetylcysteine prevents baker's-yeast-induced inflammation and fever. Inflammation Research 61, 103–112.

    Not in our library10.1007/s00011-011-0392-8

  38. 38.

    Fineberg AM and Ellman LM (2013 ) Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biological Psychiatry 73, 951–966.

    Not in our library10.1016/j.biopsych.2013.01.001

  39. 39.

    Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, Griffith L, Oremus M, Raina P, Ismaila A, Santaguida P, Lau J and Trikalinos TA (2011 ) Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. Journal of Clinical Epidemiology 64, 1187–1197.

    Not in our library10.1016/j.jclinepi.2010.08.010

  40. 40.

    Ghafari E, Fararouie M, Shirazi HG, Farhangfar A, Ghaderi F and Mohammadi A (2013 ) Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Clinical Schizophrenia & Related Psychoses 6, 172–176.

    Not in our library

  41. 41.

    Ghanizadeh A, Dehbozorgi S, OmraniSigaroodi M and Rezaei Z (2014 ) Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial. Recent Patents on Inflammation & Allergy Drug Discovery 8, 211–215.

    Not in our library10.2174/1872213x08666141029123524

  42. 42.

    Gipson CD (2016 ) Treating addiction: unraveling the relationship between N-acetylcysteine, glial glutamate transport, and behavior. Biological Psychiatry 80, e11–e12.

    Not in our library10.1016/j.biopsych.2016.05.007

  43. 43.

    Glantz LA and Lewis DA (2000 ) Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Archives of General Psychiatry 57, 65–73.

    Not in our library10.1001/archpsyc.57.1.65

  44. 44.

    Grommes C, Karlo JC, Caprariello A, Blankenship D, Dechant A and Landreth GE (2013 ) The PPARgamma agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemotherapy and Pharmacology 71, 929–936.

    Not in our library10.1007/s00280-013-2084-2

  45. 45.

    Guclu F, Ozmen B, Hekimsoy Z and Kirmaz C (2004 ) Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomedicine and Pharmacotherapy 58, 614–618.

    Not in our library10.1016/j.biopha.2004.09.005

  46. 46.

    Haynes W (2013 ) Bonferroni correction In Dubitzky W, Wolkenhauer O, Cho KH and Yokota H (eds), Encyclopedia of Systems Biology. New York: Springer, pp. 154–154.

    Not in our library

  47. 47.

    Higgins JPT and Green S (2008 ) Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: Wiley-Blackwell.

    Not in our library

  48. 48.

    Higgins JP, Thompson SG, Deeks JJ and Altman DG (2003 ) Measuring inconsistency in meta-analyses. British Medical Journal 327, 557–560.

    Not in our library10.1136/bmj.327.7414.557

  49. 49.

    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L and Sterne JA (2011 ) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 343, d5928.

    Not in our library10.1136/bmj.d5928

  50. 50.

    Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J and Nye A (2011 ) Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Archives of General Psychiatry 68, 1195–1206.

    Not in our library10.1001/archgenpsychiatry.2011.83

  51. 51.

    Inta D, Lang UE, Borgwardt S, Meyer-Lindenberg A and Gass P (2017 ) Microglia activation and schizophrenia: lessons from the effects of minocycline on postnatal neurogenesis, neuronal survival and synaptic pruning. Schizophrenia Bulletin 43, 493–496.

    Not in our library10.1093/schbul/sbw088

  52. 52.

    Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S, Zeionoddini A, Mohammadinejad P, Zeinoddini A and Akhondzadeh S (2016 ) The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Human Psychopharmacology 31, 103–112.

    Not in our library10.1002/hup.2517

  53. 53.

    Jamilian H, Solhi H and Jamilian M (2014 ) Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Global Journal of Health Science 6, 103–108.

    Not in our library10.5539/gjhs.v6n7p103

  54. 54.

    Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J and Marder SR (2012 ) Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research 136, 25–31.

    Not in our library10.1016/j.schres.2011.11.001

  55. 55.

    Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM and Buchanan RW (2015 ) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. Journal of Clinical Psychopharmacology 35, 374–381.

    Not in our library10.1097/jcp.0000000000000345

  56. 56.

    Khan B, Ahmad SF, Bani S, Kaul A, Suri KA, Satti NK, Athar M and Qazi GN (2006 ) Augmentation and proliferation of T lymphocytes and Th-1 cytokines by Withania somnifera in stressed mice. International Immunopharmacology 6, 1394–1403.

    Not in our library10.1016/j.intimp.2006.04.001

  57. 57.

    Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M and Akhondzadeh S (2014 ) Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Research 215, 540–546.

    Not in our library10.1016/j.psychres.2013.12.051

  58. 58.

    Khodaie-Ardakani MR, Khosravi M, Zarinfard R, Nejati S, Mohsenian A, Tabrizi M and Akhondzadeh S (2015 ) A placebo-controlled study of raloxifene added to risperidone in men with chronic schizophrenia. Acta Medica Iranica 53, 337–345.

    Not in our library

  59. 59.

    Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L and Akhondzadeh S (2014 ) Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences 22, 55.

    Not in our library10.1186/2008-2231-22-55

  60. 60.

    Koola MM (2018 ) Can Nacetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity? Schizophrenia Research. 206, 452–453.

    Not in our library10.1016/j.schres.2018.11.022

  61. 61.

    Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, Hoffman S, Francuski M, Kunert C, Kuecuek O, Schumacher G, Wesslau C, Lun A, Kohler S, Weiss S, Tullius SG, Neuhaus P and Pratschke J (2008 ) Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Annals of Surgery 248, 1042–1050.

    Not in our library10.1097/sla.0b013e318190e70c

  62. 62.

    Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J and Burger H (2001 ) Estrogen - a potential treatment for schizophrenia. Schizophrenia Research 48, 137–144.

    Not in our library10.1016/s0920-9964(00)00088-8

  63. 63.

    Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C and Burger H (2008 ) Estrogen in severe mental illness: a potential new treatment approach. Archives of General Psychiatry 65, 955–960.

    Not in our library10.1001/archpsyc.65.8.955

  64. 64.

    Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S, Gurvich C, Fitzgerald PB and Burger H (2011 ) Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophrenia Research 125, 278–283.

    Not in our library10.1016/j.schres.2010.10.009

  65. 65.

    Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M and Davis SR (2016 ) Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry 73, 947–954.

    Not in our library10.1001/jamapsychiatry.2016.1383

  66. 66.

    Kumar G and Patnaik R (2016 ) Exploring neuroprotective potential of Withania somnifera phytochemicals by inhibition of GluN2B-containing NMDA receptors: an in silico study. Medical Hypotheses 92, 35–43.

    Not in our library10.1016/j.mehy.2016.04.034

  67. 67.

    Kurosawa T, Higuchi K, Okura T, Kobayashi K, Kusuhara H and Deguchi Y (2017 ) Involvement of proton-coupled organic cation antiporter in varenicline transport at blood-brain barrier of rats and in human brain capillary endothelial cells. Journal of Pharmaceutical Sciences 106, 2576–2582.

    Not in our library10.1016/j.xphs.2017.04.032

  68. 68.

    Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS and Burger H (2010 ) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 71, 520–527.

    Not in our library10.4088/jcp.09m05117yel

  69. 69.

    Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang LJ, Lee IH, Wang TY, Chen KC, Yang YK, Hong JS and Lu RB (2015 ) ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan. Journal of Psychiatric Research 69, 50–56.

    Not in our library10.1016/j.jpsychires.2015.07.027

  70. 70.

    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R and Ritsner MS (2013 ) The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. Journal of Clinical Psychiatry 74, 1224–1232.

    Not in our library10.4088/jcp.12m08160

  71. 71.

    Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I and Kron S (2010 ) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. Journal of Clinical Psychiatry 71, 138–149.

    Not in our library10.4088/jcp.08m04666yel

  72. 72.

    Liu X, Fan XL, Zhao Y, Luo GR, Li XP, Li R and Le WD (2005 ) Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. Journal of Neuroscience Research 81, 653–665.

    Not in our library10.1002/jnr.20583

  73. 73.
    A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy · 2013
    No notice
  74. 74.

    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X and Zhao J (2014 ) Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophrenia Research 153, 169–176.

    Not in our library10.1016/j.schres.2014.01.011

  75. 75.

    Liu F, Zhang B, Xie L, Ruan Y, Xu X, Zeng Y, Messina L, Zhao J and Fan X (2018 ) Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. Schizophrenia Research 199, 390–394.

    Not in our library10.1016/j.schres.2018.03.003

  76. 76.

    Louza MR, Marques AP, Elkis H, Bassitt D, Diegoli M and Gattaz WF (2004 ) Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophrenia Research 66, 97–100.

    Not in our library10.1016/s0920-9964(03)00082-3

  77. 77.

    Man L, Lv X, Du XD, Yin G, Zhu X, Zhang Y, Soares JC, Yang XN, Chen X and Zhang XY (2018 ) Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Research 263, 1–6.

    Not in our library10.1016/j.psychres.2018.02.034

  78. 78.

    Markoutsa E and Xu P (2017 ) Redox potential-sensitive N-acetyl cysteine-prodrug nanoparticles inhibit the activation of microglia and improve neuronal survival. Molecular Pharmaceutics 14, 1591–1600.

    Not in our library10.1021/acs.molpharmaceut.6b01028

  79. 79.
    Immunomodulatory Effects of 17β-Estradiol on Epithelial Cells during Bacterial Infections · 2018
    Not checked
  80. 80.

    Miller BJ and Buckley PF (2016 ). The Case for Adjunctive Monoclonal Antibody Immunotherapy in Schizophrenia. Psychiatric Clinics of North America 39, 187–198.

    Not in our library10.1016/j.psc.2016.01.003

  81. 81.

    Misiak B, Stanczykiewicz B, Kotowicz K, Rybakowski JK, Samochowiec J and Frydecka D (2018 ) Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review. Schizophrenia Research 192, 16–29.

    Not in our library10.1016/j.schres.2017.04.015

  82. 82.

    Modabbernia A, Heidari P, Soleimani R, Sobhani A, Roshan ZA, Taslimi S, Ashrafi M and Modabbernia MJ (2014 ) Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. Journal of Psychiatric Research 53, 133–140.

    Not in our library10.1016/j.jpsychires.2014.02.013

  83. 83.

    Moher D, Liberati A, Tetzlaff J and Altman DG (2009 ) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 62, 1006–1012.

    Not in our library10.1016/j.jclinepi.2009.06.005

  84. 84.

    Mokhtari R and Lachman HM (2016 ) The Major Histocompatibility Complex (MHC) in schizophrenia: a review. Journal of Clinical & Cellular Immunology 7, 479.

    Not in our library10.4172/2155-9899.1000479

  85. 85.

    Mulabagal V, Subbaraju GV, Rao CV, Sivaramakrishna C, Dewitt DL, Holmes D, Sung B, Aggarwal BB, Tsay HS and Nair MG (2009 ) Withanolide sulfoxide from Aswagandha roots inhibits nuclear transcription factor-kappa-B, cyclooxygenase and tumor cell proliferation. Phytotherapy Research 23, 987–992.

    Not in our library10.1002/ptr.2736

  86. 86.

    Mulders-Manders CM, Baas MC, Molenaar FM and Simon A (2017 ) Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature. Frontiers in Pharmacology 8, 342.

    Not in our library10.3389/fphar.2017.00342

  87. 87.

    Muller N and Schwarz M (2006 ) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research 10, 131–148.

    Not in our library10.1007/bf03033242

  88. 88.

    Muller N and Dursun SM (2011 ) Schizophrenia genes, epigenetics and psychoneuroimmunology therapeutics: all make sense now? Journal of Psychopharmacology 25, 713–714.

    Not in our library10.1177/0269881110364268

  89. 89.

    Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ and Schwarz MJ (2002 ) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159, 1029–1034.

    Not in our library10.1176/appi.ajp.159.6.1029

  90. 90.

    Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Moller HJ, Klauss V, Schwarz MJ and Riedel M (2010 ) Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Research 121, 118–124.

    Not in our library10.1016/j.schres.2010.04.015

  91. 91.

    Murugan S, Jakka P, Namani S, Mujumdar V and Radhakrishnan G (2019 ) The neurosteroid, pregnenolone promotes degradation of key proteins in the innate immune signalling to suppress inflammation. Journal of Biological Chemistry 294, 4596–4607.

    Not in our library10.1074/jbc.ra118.005543

  92. 92.

    Naert G, Maurice T, Tapia-Arancibia L and Givalois L (2007 ) Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 32, 1062–1078.

    Not in our library10.1016/j.psyneuen.2007.09.002

  93. 93.

    Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R and Verri WA Jr. (2013 ) Analgesic activity of piracetam: effect on cytokine production and oxidative stress. Pharmacology, Biochemistry and Behavior 105, 183–192.

    Not in our library10.1016/j.pbb.2013.02.018

  94. 94.

    Nimgaonkar VL, Prasad KM, Chowdari KV, Severance EG and Yolken RH (2017 ) The complement system: a gateway to gene-environment interactions in schizophrenia pathogenesis. Molecular Psychiatry 22, 1554–1561.

    Not in our library10.1038/mp.2017.151

  95. 95.

    Noorbala AA, Akhondzadeh S, Davari-Ashtiani R and Amini-Nooshabadi H (1999 ) Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics 24, 369–374.

    Not in our library10.1046/j.1365-2710.1999.00238.x

  96. 96.

    Nye EJ, Hockings GI, Grice JE, Torpy DJ, Walters MM, Crosbie GV, Wagenaar M, Cooper M and Jackson RV (1997 ) Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans. Journal of Clinical Endocrinology and Metabolism 82, 812–817.

    Not in our library10.1210/jcem.82.3.3820

  97. 97.

    O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, Churchill M, Eckhoff PJ, Weaver A, Doud D, Erikson N, Dietz F, Olson R, Maloley P, Klassen LW and Moore GF (1997 ) Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 40, 842–848.

    Not in our library10.1002/art.1780400510

  98. 98.

    Palacio JR, Markert UR and Martinez P (2011 ) Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflammation Research 60, 695–704.

    Not in our library10.1007/s00011-011-0323-8

  99. 99.

    Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E and Pawelczyk A (2016 ) A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. Journal of Psychiatric Research 73, 34–44.

    Not in our library10.1016/j.jpsychires.2015.11.013

  100. 100.

    Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E and Tershakovec AM (2009 ) Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. American Journal of Cardiology 103, 369–374.

    Not in our library10.1016/j.amjcard.2008.09.090

  101. 101.

    Peet M and Horrobin DF (2002 ) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36, 7–18.

    Not in our library10.1016/s0022-3956(01)00048-6

  102. 102.

    Peet M, Brind J, Ramchand CN, Shah S and Vankar GK (2001 ) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 49, 243–251.

    Not in our library10.1016/s0920-9964(00)00083-9

  103. 103.

    Pettit LK, Varsanyi C, Tadros J and Vassiliou E (2013 ) Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin. Lipids in Health and Disease 12, 16.

    Not in our library10.1186/1476-511x-12-16

  104. 104.

    Presumey J, Bialas AR and Carroll MC (2017 ) Complement system in neural synapse elimination in development and disease. Advances in Immunology 135, 53–79.

    Not in our library10.1016/bs.ai.2017.06.004

  105. 105.

    Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR and Pozo D (2006 ) NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Annals of the New York Academy of Sciences 1070, 500–506.

    Not in our library10.1196/annals.1317.069

  106. 106.

    Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O and Dolnak D (2005 ) Celecoxib augmentation of continuously ill patients with schizophrenia. Biological Psychiatry 57, 1594–1596.

    Not in our library10.1016/j.biopsych.2005.02.024

  107. 107.

    Rappard F and Muller N (2004 ) Celecoxib add-on does not have beneficial antipsychotic effects over risperidone alone in schizophrenia [abstract]. Neuropsychopharmacology 29, S183–S241.

    Not in our library

  108. 108.

    Ridker PM, Rifai N, Pfeffer MA, Sacks F and Braunwald E (1999 ) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100, 230–235.

    Not in our library10.1161/01.cir.100.3.230

  109. 109.

    Ritsner MS, Bawakny H and Kreinin A (2014 ) Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry and Clinical Neurosciences 68, 432–440.

    Not in our library10.1111/pcn.12150

  110. 110.

    Rosas-Ballina M and Tracey KJ (2009 ) Cholinergic control of inflammation. Journal of Internal Medicine 265, 663–679.

    Not in our library10.1111/j.1365-2796.2009.02098.x

  111. 111.

    Rosenthal R (1991 ) Meta-Analytic Procedures for Social Research. Newbury Park, CA: Sage Publications.

    Not in our library

  112. 112.

    Roth GJ and Majerus PW (1975 ) The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. Journal of Clinical Investigation 56, 624–632.

    Not in our library10.1172/jci108132

  113. 113.

    Sadli N, Ackland ML, De Mel D, Sinclair AJ and Suphioglu C (2012 ). Effects of zinc and DHA on the epigenetic regulation of human neuronal cells. Cellular Physiology and Biochemistry 29, 87–98.

    Not in our library10.1159/000337590

  114. 114.

    Sanchez MG, Morissette M and Di Paolo T (2012 ) Effect of a chronic treatment with 17beta-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys. Psychoneuroendocrinology 37, 280–291.

    Not in our library10.1016/j.psyneuen.2011.06.012

  115. 115.

    Schizophrenia Working Group of the Psychiatric Genomics (2014 ) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421.

    Not in our library10.1038/nature13595

  116. 116.

    Schwarz E, van Beveren NJ, Ramsey J, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Guest PC and Bahn S (2014 ) Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophrenia Bulletin 40, 787–795.

    Not in our library10.1093/schbul/sbt105

  117. 117.

    Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE, Daly MJ, Carroll MC, Stevens B and McCarroll SA (2016 ) Schizophrenia risk from complex variation of complement component 4. Nature 530, 177–183.

    Not in our library10.1038/nature16549

  118. 118.

    Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, Fu T, Worringer K, Brown HE, Wang J, Kaykas A, Karmacharya R, Goold CP, Sheridan SD and Perlis RH (2019 ) Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nature Neuroscience 22, 374–385.

    Not in our library10.1038/s41593-018-0334-7

  119. 119.

    Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H and Heidary M (2018 ) Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: a double-blind, randomized clinical trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry 82, 289–296.

    Not in our library10.1016/j.pnpbp.2017.11.001

  120. 120.

    Shaddish W and Haddock C (1994 ) Combining estimates of effect size. In The Handbook of Research Synthesis (ed. H. Coopers and V. Hedges ), pp. 261–281. Sage Publications: New York.

    Not in our library

  121. 121.

    Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA and Burgos JS (2011 ) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. Journal of Alzheimer's Disease 23, 307–318.

    Not in our library10.3233/jad-2010-101179

  122. 122.

    Simon LS (1999 ) Role and regulation of cyclooxygenase-2 during inflammation. American Journal of Medicine 106, 37s–42s.

    Not in our library10.1016/s0002-9343(99)00115-1

  123. 123.

    Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M and Davis JM (2016 ) Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial. PloS One 11, e0143490.

    Not in our library10.1371/journal.pone.0143490

  124. 124.

    Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Capurso A and Panza F (2010 ) Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Research Reviews 9, 184–199.

    Not in our library10.1016/j.arr.2009.07.005

  125. 125.

    Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S and Kahn RS (2014 ) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophrenia Bulletin 40, 181–191.

    Not in our library10.1093/schbul/sbt139

  126. 126.

    Sripada RK, Marx CE, King AP, Rampton JC, Ho SS and Liberzon I (2013 ) Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biological Psychiatry 73, 1045–1053.

    Not in our library10.1016/j.biopsych.2012.12.008

  127. 127.

    Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N, Shariat SV, Rezaei F, Salehi B and Akhondzadeh S (2017 ) Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. International Clinical Psychopharmacology 32, 87–94.

    Not in our library10.1097/yic.0000000000000159

  128. 128.

    Takao K, Kobayashi K, Hagihara H, Ohira K, Shoji H, Hattori S, Koshimizu H, Umemori J, Toyama K, Nakamura HK, Kuroiwa M, Maeda J, Atsuzawa K, Esaki K, Yamaguchi S, Furuya S, Takagi T, Walton NM, Hayashi N, Suzuki H, Higuchi M, Usuda N, Suhara T, Nishi A, Matsumoto M, Ishii S and Miyakawa T (2013 ) Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology 38, 1409–1425.

    Not in our library10.1038/npp.2013.38

  129. 129.

    Tousi B (2015 ) The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence. Neuropsychiatric Disease and Treatment 11, 311–315.

    Not in our library10.2147/ndt.s61309

  130. 130.

    Upthegrove R, Manzanares-Teson N and Barnes NM (2014 ) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophrenia Research 155, 101–108.

    Not in our library10.1016/j.schres.2014.03.005

  131. 131.

    Usall J, Huerta-Ramos E, Labad J, Cobo J, Nunez C, Creus M, Pares GG, Cuadras D, Franco J, Miquel E, Reyes JC and Roca M (2016 ) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Schizophrenia Bulletin 42, 309–317.

    Not in our library10.1093/schbul/sbv149

  132. 132.

    van Beveren NJ, Schwarz E, Noll R, Guest PC, Meijer C, de Haan L and Bahn S (2014 ) Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Translational Psychiatry 4, e430.

    Not in our library10.1038/tp.2014.52

  133. 133.

    Vane JR, Bakhle YS and Botting RM (1998 ) Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 38, 97–120.

    Not in our library10.1146/annurev.pharmtox.38.1.97

  134. 134.

    Vasovic V, Banic B, Jakovljevic V, Tomic Z and Milic-Djordjevic V (2008 ) Effect of aminophylline on aspirin penetration into the central nervous system in rats. European Journal of Drug Metabolism and Pharmacokinetics 33, 23–30.

    Not in our library10.1007/bf03191015

  135. 135.

    Vincenzi B, Stock S, Borba CP, Cleary SM, Oppenheim CE, Petruzzi LJ, Fan X, Copeland PM, Freudenreich O, Cather C and Henderson DC (2014 ) A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophrenia Research 159, 395–403.

    Not in our library10.1016/j.schres.2014.08.021

  136. 136.

    Wakade CG, Mahadik SP, Waller JL and Chiu FC (2002 ). Atypical neuroleptics stimulate neurogenesis in adult rat brain. Journal of Neuroscience Research 69, 72–79.

    Not in our library10.1002/jnr.10281

  137. 137.

    Watabe M, Kato TA, Monji A, Horikawa H and Kanba S (2012 ) Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction? Psychopharmacology 220, 551–557.

    Not in our library10.1007/s00213-011-2509-8

  138. 138.

    Weiser M, Burshtein S and Fodoreanu L (2012 ) A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder [abstract]. Neuropsychopharmacology 38, S314–S446.

    Not in our library

  139. 139.

    Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, Miclutia I, Tiugan A, Pacala B, Grecu IG, Noy A, Zamora D and Davis JM (2017 ) Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely Ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. Journal of Clinical Psychiatry 78, e758–e765.

    Not in our library10.4088/jcp.15m10498

  140. 140.

    Weiser M, Levi L, Burshtein S, Chirita R, Cirjaliu D, Gonen I, Yolken R, Davidson M, Zamora D and Davis JM (2019 ) The effect of minocycline on symptoms in schizophrenia: results from a randomized controlled trial. Schizophrenia Research 206, 325–332.

    Not in our library10.1016/j.schres.2018.10.023

  141. 141.

    Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, Steffens S, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C, Zipfel PF, Skerka C and Habenicht AJR (2019 ) Apoe attenuates unresolvable inflammation by complex formation with activated C1q. Nature Medicine 25, 496–506.

    Not in our library10.1038/s41591-018-0336-8

  142. 142.

    Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T and Koistinaho J (1998 ) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proceedings of the National Academy of Sciences of the United States of America 95, 15769–15774.

    Not in our library10.1073/pnas.95.26.15769

  143. 143.

    Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, Zhang W, Hong JS and Liu B (2004 ) Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB Journal 18, 589–591.

    Not in our library10.1096/fj.03-0983fje

  144. 144.

    Zhang J-h, Chen B and Jian-rui L (2015 ) Treatment effect of risperidone alone and combined with N-acetly-cysteine for first-episode schizophrenic patients [Chinese article]. Journal of Clinical Psychiatry 25, 394–396.

    Not in our library

  145. 145.

    Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY and Zhao J (2018 ) Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: association with pro-inflammatory cytokine levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry 85, 69–76.

    Not in our library10.1016/j.pnpbp.2018.04.004

  146. 146.

    Zheng W, Cai DB, Yang XH, Ungvari GS, Ng CH, Muller N, Ning YP and Xiang YT (2017 ) Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Journal of Psychiatric Research 92, 139–146.

    Not in our library10.1016/j.jpsychires.2017.04.004

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.